Abstract: T-type Ca 2ϩ channels encoded by voltage-gated Ca 2ϩ channel (Ca v ) 3.1, 3.2, and 3.3 genes play important physiological roles and serve as therapeutic targets for neurological and cardiovascular disorders. Currently there is no selective T-channel blocker. To screen for such a blocker, we developed three stable cell lines expressing human recombinant Ca v 3.1, 3.2, or 3.3 channels and then examined their usefulness in high throughput screens. All three cell lines displayed an increase in intracellular Ca 2ϩ in response to changes in extracellular Ca 2ϩ as detected with Ca 2ϩ -sensitive dyes using a fluorometric imaging plate reader (FLIPR ® [Molecular Devices, Sunnyvale, CA] or FlexStation ® [Molecular Devices]). The signal-to-noise ratio was 2-4. Coexpression of Ca v 3.2 with a mouse leak K ϩ channel, which by virtue of being open at rest hyperpolarizes the cell membrane, blocked the fluorescent signal. Co-addition of KCl to these cells induced a Ca 2ϩ signal that was similar to that observed in the cell line expressing Ca v 3.2 alone. These results confirm that the detection of intracellular Ca 2ϩ increase in cells expressing Ca v 3.2 alone results from Ca 2ϩ entry through channels that are open at the resting membrane potential of each cell line (i.e., window currents). Testing known drugs on Ca v 3 channels showed that block could be reliably detected using the FlexStation assay, FLIPR assay, or voltage clamp recordings using the IonWorks ® HT system (Molecular Devices). These results support the use of the FLIPR window current assay for primary drug screening and high throughput patch recordings for secondary screening of novel T-channel blockers.
Introduction

T
-TYPE CA 2ϩ CHANNELS are also called low voltageactivated channels because they open at voltages near the resting membrane potential of most cells. In many types of neurons, Ca 2ϩ influx through T-type channels triggers low-threshold spikes, which in turn trigger a burst of action potentials mediated by Na ϩ channels. 1 Burst firing is thought to play an important role in the synchronized activity of the thalamus observed in absence epilepsy, and also in a wider range of neurological disorders characterized by thalamocortical dysrhythmia. 2 Prominent T-currents are also observed in dorsal root ganglion neurons, with subsets of nociceptors expressing more T-current than high voltage-activated Ca 2ϩ currents. 3 Considerable evidence supports the notion that a T-channel antagonist would be a useful drug for the treatment of pain and epilepsy. 4 Nevertheless, elucida-tion of the physiologic and pharmacologic roles of T-type Ca 2ϩ channels has been limited by the availability of selective and potent inhibitors. For example, the precise role T-channels play in the cardiovascular system remains controversial. Mibefradil, a potent T-channel blocker that also blocks L-type channels, is an effective antihypertensive agent; however, whether T-channel blockade contributed to its mechanism of action has been recently challenged. 5 Molecular cloning revealed the existence of three Ttype channel genes, designated voltage-gated Ca 2ϩ channel (Ca v ) 3.1, 3.2, and 3.3 (also termed ␣1G, ␣1H, and ␣1I). Ca v 3.1 and Ca v 3.3 subtypes are expressed predominantly, though not exclusively, in the brain. In contrast, the Ca v 3.2 subtype is also present in the central nervous system, but appears to be relatively more abundant in several nonneuronal tissues, including heart, kidney, adrenal, and pituitary. 1 Deletion of the genes encoding Ca v 3 channels and studies of the resultant phenotypes have shed light on these aspects. Results from studies on Ca v 3.1 (␣1G) Ca 2ϩ channel knockout mice support the notion that T-currents are responsible for the generation of the slow wave spikes in the thalamus that are involved in epileptogenesis of absence seizures and sleep regulation. 6, 7 In contrast, peripheral T-current inhibition with mibefradil produces analgesic effects. [8] [9] [10] The main target for these effects is Ca v 3.2, since disruption of its expression using either antisense oligonucleotides or transgenic mice produces analgesia. 11, 12 It is hypothesized that subtype-selective Ca v 3 modulators should produce more specific pharmacological actions for a variety of neurological, psychiatric, and cardiovascular disorders, with fewer side effects. HTS of a large compound library is the initial step toward identifying such novel compounds.
The "gold standard" technology to study ion channels is with electrophysiologic techniques using whole-cell voltage-clamp recordings. However, the T-currents in native cells are usually very small (Ͻ100 pA). 1 In contrast, recombinant channels can be expressed at much higher levels (500-2,000 pA). 13 Notably, the electrophysiologic properties of recombinant Ca v 3 channels are similar to those of native T-type currents. 1 These cell lines offer a valuable tool for drug screening, yet screening by electrophysiologic techniques are laborious and time-consuming, and an HTS format for primary drug screening is difficult to achieve, even with the recently developed high throughput electrophysiology technology. 14, 15 In this study we explore the possibility that T-channel activity can be assayed using a fluorometric method in HTS format. This assay exploits that ability of T-channels to open at the resting membrane potential of many cells, thereby producing a "window" current. 16 Chemin et al. 17 showed that recombinant T-channels also showed this activity when expressed in human embryonic kidney 293 (HEK293) cells; increasing 18 In the present study we used a background K ϩ channel to confirm that these Ca-induced changes in fluorescence were attributable to T-channel window currents. We also show that all three Ca v 3 channels subtypesCa v 3.1, 3.2, and 3.3-are capable of generating this [Ca 2ϩ ] i signal. We describe conditions that optimize the detection and reproducibility of these signals on a fluorometric imaging plate reader (FLIPR ® , Molecular Devices, Sunnyvale, CA). Finally, we show that these cell lines are suitable for use in an Ionworks ® HT planar patch system, and compared the potency of a set of compounds determined by both fluorometric method and patch recording techniques.
Materials and Methods
Cell culture
Creation of HEK293 cell lines expressing human recombinant Ca v 3.1, 3.2, and 3.3 channels has been described previously. 13 All three cell lines were grown as monolayers in Dulbecco's Modified Eagle's Medium containing 4.5 g/L D-glucose, pyroxidine hydrochloride, and 0.5 mM CaCl 2 , supplemented with 10% fetal bovine serum, 1 mg/ml geneticin, 4 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. A fourth cell line was created by transfecting HEK293 cells with two plasmids: one containing human Ca v 3.2 (conferring geneticin resistance), and the other containing a truncated mouse K ϩ channel, the TWIK-1-related K ϩ channel called TREK-1 (conferring puromycin resistance). 19 For measurement of [Ca 2ϩ ] i using the fluorometric methods, cells were seeded into clear-bottom (either clear or blackwalled) 96-well microtiter plates that were coated with poly-D-lysine (Becton-Dickinson, Franklin Lakes, NJ) at a concentration range of 50,000-70,000 cells per well and used for assay within approximately 12 h.
Measurement of [Ca 2ϩ ] i using Ca-sensitive dyes
Ca v 3 cells were washed with 140 mM NaCl, 5 mM KCl, 10 mM glucose, 0.5 mM CaCl 2 , and 10 mM HEPES at pH 7.4 (HBSS-HEPES buffer), using a multichannel pipettor (Multimek 96/384, Beckman Coulter, Fullerton, CA) prior to incubation with 2 M Fluo-4 acetoxymethyl ester (Fluo-4-AM) in HBSS-HEPES buffer for 30 min at 37°C. Cells were then washed again, overlaid with 100 l of HBSS-HEPES buffer, and then loaded into a FlexStation ® (Molecular Devices). For assays using Calcium 3 FLIPR dye, growth medium was removed by aspiration, 180 l of Calcium 3 reagent reconstituted in HBSS-HEPES buffer was added, and cells were loaded for 60 min at 37°C. Test drugs were added to wells at desired concentrations at room temperature and incubated for 20 min. Subsequently, the plates were placed on the FLIPR, and cells' fluorescence was monitored ( excitation ϭ 488 nm, emission ϭ 540 nm) before and after the addition of HBSS-HEPES buffer containing a single or a range of CaCl 2 concentrations (0.5-20 mM). In the initial measurements, fluorescence intensity units were measured every 1 s for 60 s; for the next 2-6 min, measurements were taken every 10 s.
All compounds were dissolved in dimethyl sulfoxide (DMSO) as a stock solution and diluted to three or four times to the final concentrations with HBSS-HEPES buffer. Effects of DMSO on basal [Ca 2ϩ ] i assays were assessed. Concentrations below 0.3% have little effect, 0.3% decreased basal activity ϳ15%, while higher concentrations were clearly inhibitory. Therefore 0.3% DMSO was selected as the maximum.
Data analysis of FlexStation data
Fluorescence signals were acquired for 60 s and then analyzed using SoftMax Pro software (version 4.8, Molecular Devices). The initial 15 s of baseline were used to zero the signal, and the remaining signal was integrated using the area under the curve function. The results were exported to Excel (Microsoft, Bellevue, WA) spreadsheets. The results were normalized to the buffer control, averaged, and then fit with the following form of the HillLangmuir equation using the Solver function:
where B represents fractional block at the drug concentration D, h is the Hill coefficient, and IC 50 is the concentration of half-maximal block (half of the maximum inhibitory response). Drug concentrations were converted to the base 10 logarithm. Figures were generated using Prism ® software (GraphPad Software, San Diego, CA), and the smooth curves represent fits (same equation) to the average.
Data analysis of FLIPR data
A dilution/mechanical artifact always occurs on addition of the stimulus. Therefore, basal fluorescence was defined as that measured in the data point following the addition of the buffer stimulus. The peak value was measured by the maximum -minimum method. Data were represented as mean Ϯ standard error of the mean of three to eight wells, and most experiments were repeated at least twice. High throughput assays can rapidly generate large datasets, and an automated or semiautomated process of data analysis is critical to HTS. The current proprietary FLIPR software can automatically quantitatively detect the signals and export them as text or Excel files. To facilitate analysis of these data, SRI (Menlo Park, CA) developed a user-friendly software using a combination of MATLAB ® 1 ᎏᎏᎏ (1 ϩ (10 log((IC 50 Ϫ[D])ϫh ) (version 6.5, The MathWorks, Natick, MA) and Excel. This program has the ability to automatically identify single concentration hits for HTS use and to perform standard concentration-response curve analysis for follow-up pharmacology. The program interfaces with a custommade graphical user interface and built-in Tutorial for easy and self-taught learning.
Analyses of the FLIPR fluorescence response data were performed using algorithms programmed into MATLAB version 6.5 interfaced with a custom-made graphical user interface. The algorithm is designed to extract the maximum or minimum response peak with respect to the baseline of the sequence data. If multiple cells are selected, the algorithm calculates the average peak values, the standard deviations of the peak values, the standard error of the mean of the peak values, and the coefficient of variation (CV) of the peak values. Student's two-tail t test was used to calculate 95% confidence intervals. As an option, the user can also select wells that are defined as positive or negative controls.
Analyses of dose-response data were done using algorithms programmed in MATLAB version 6.5. The peak values and their respective confidence intervals were plotted as a function of the concentration values (in logarithmic base 10). The data were then fitted to a sigmoidal curve using least square fit (Eq. 1, adapted from SigmaPlot, Systat, San Jose, CA). The IC 50 value was extracted from the best-fit curve using one of the following equations (see Fig. 4 ):
In Eq. 1, a defines the amplitude, b is the y-intercept, c is the slope of the curve, and x is the compound concentration. A second equation was also used to fit the data (Eq. 2), using the same variables as Eq. 1:
Both are logistic equations derived from the Hill-Langmuir equation. Equation 1 produces better fits (i.e., smallest least square error) when in cases of incomplete block. Future development will expand the analyzed data to be stored in a database and associate them with the metadata describing the experiment (compounds, experimental conditions and protocol, etc.). The information should be combined with the raw and analyzed data and stored in a secure file system and database.
Assay quality control
A screening window coefficient, "Z-factor," which reflects both the assay signal dynamic range and the data
variation associated with the signal measurements, 20 was used to assess the assay quality. The Z-factor from the negative control (normal buffer containing 0.5 mM Ca) of three separate assays (plate-to-plate variability) was calculated as 0.5, indicating the consistency of the assay. For the positive control, a Z-factor of 0.5 was calculated from eight wells of maximal inhibition produced by a plateau concentration of mibefradil (30 M) and control (10 mM Ca) in the same plate. However, in separate assays, the same experiment yielded a Z-factor of approximately 0.4, indicating that results of drug testing are more variable than those of the assay per se.
Patch clamp recording
Conventional patch clamp recording techniques were used for characterization of the three Ca v 3 channels expressed in HEK293 cell lines as described previously. 21 The IonWorks Quattro™ HT planar patch clamp system was used to test a number of known T-channel modulators with Ca v 3 channels. Cells were bathed with an extracellular solution containing 2 mM CaCl 2 , 140 mM tetraethylammonium chloride, 6 mM CsCl, 0.1 mM EDTA, and 10 mM HEPES (pH adjusted to 7.4 with CsOH) at room temperature. The intracellular solution contained 55 mM CsCl, 75 mM CsSO 4 , 10 mM MgCl 2 , 0.1 mM EGTA, and 10 mM HEPES (pH adjusted to 7.2 with CsOH) plus 10 g/ml amphotericin B. T-current amplitudes ranged from 50 to 500 pA when the extracellular solution contained 2 mM Ca 2ϩ as charge carrier. Baseline current traces and after-compound application were recorded. Concentration-dependent inhibitory curves were constructed to estimate the IC 50 of the test compounds.
Materials
Cell culture media and supplements were purchased from Gibco Invitrogen (Invitrogen, Carlsbad, CA). The following materials were obtained from the sources indicated: fetal bovine serum from Hyclone (Logan, UT), Calcium 3 FLIPR dye from Molecular Devices, and Fluo-4-AM from Molecular Probes (Eugene, OR). All other reagents and test drugs were purchased from SigmaAldrich (St. Louis, MO). The mibefradil used in the FLIPR and IonWorks was obtained from Sigma-Aldrich, while mibefradil used in the FlexStation assay was a gift from Hoffmann-La Roche (Basel, Switzerland).
Results
Validation of Ca-dye-based assay of recombinant Ca v 3 T-type Ca 2ϩ channels
HEK293 cells are widely used to characterize voltagegated channels because they have little or no endogenous channels under normal culture conditions, and because they express high levels of protein from plasmids containing the cytomegalovirus promoter. These cells have proven useful for studying T-channels as well, 21 and robust currents can be measured using either conventional or planar patch clamp recording (Fig. 1) . To develop a Ca-dye-based assay, these cells were loaded with Fluo-4-AM, washed, and then assayed using a FlexStation. Addition of Ca 2ϩ (10 mM final concentration) led to an increase in fluorescence in cells transfected with Ca v 3.2, but not in untransfected cells (Fig. 2A) . This Ca-induced signal in Ca v 3.2 cells could be attenuated by preincubation with mibefradil ( Fig. 2A) . A similar Ca-induced rise in fluorescence was measured in stable cell lines expressing human recombinant Ca v 3.1 and Ca v 3.3 (Fig.  2B) . The Ca-dye signal was proportional to the size of the currents measured by whole cell electrophysiology, with the Ca v 3.3 line expressing the largest signal in both assays. If these signals were attributable to window currents via T-channels, which typically operate between Ϫ80 and Ϫ30 mV, 1 then hyperpolarization of the cell membrane would be expected to eliminate the current, and make it responsive to depolarization. This hypothesis was tested in a cell line expressing both Ca v 3.2 and a K ϩ channel that is open at rest (leak channel), such as TREK-1. 22 The resting membrane potential of these cells is Ϫ83 mV. 19 Addition of Ca alone to these cells did not induce a fluorescent signal. Simultaneous addition of CaCl 2 and 25 mM KCl to these cells produced a robust fluorescent signal in the FlexStation assay (Fig. 2C ). As predicted from the Nernst equation, the membrane potential could be adjusted by increasing the concentration of KCl in the Ca v 3.2-TREK cell line (Fig. 2D, inset) . Accordingly, these cells exhibited a biphasic response to increasing concentrations of KCl (Fig. 2D) , showing a small response to 5 mM KCl (V m ϭ Ϫ60 mV), peaking at 25 mM (V m ϭ Ϫ31 mV), and then falling at 50 mM (V m ϭ Ϫ19 mV). These responses are consistent with the voltage dependence of T-window currents. 1 In contrast, the cell line expressing Ca v 3.2 alone showed only a decrease in fluorescence as KCl was increased. Since the maximal responses in both cell lines were similar (Fig.  2D) , we conclude that the membrane potential of the Ca v 3.2 alone cell line was already near optimal for the window current under control conditions. These results establish that Ca v 3.2 window currents underlie the increase in fluorescence detected after a bolus of Ca is added, and support the use of this signal in a high throughput assay. Although both cell lines produced similar signals under appropriate conditions, we selected the Ca v 3.2 alone cell line for further study because of the possibility that drugs might modulate TREK channel activity, thereby obscuring their effect on the T-channel.
Optimization of FlexStation and FLIPR assay conditions
Cell density. Cell densities used in fluorescence assays vary depending on the individual cell line and attachment to matrix-coated plates. We routinely used the 96-well microtiter plates coated with poly-D-lysine. We tested a range of the cell seeding density from 30,000 to 100,000 cells per well for 96-well plates and found the optimal cell density to be 60,000-80,000. After overnight culture (10-12 h) a uniform, 80-90% confluent monolayer was formed on the day of the assay. Cell plate signal tests indicated by the CV% varied from 8% to 12% among the three cell lines ("yellow" plate background signal tests were around 1.5-3% in the FLIPR). The CV of each cell plate has direct effects on the consistency and reproducibility of the measurements. After pipettor dispensing (adding a high Ca solution) and/or compounding (without the optional mixing function), we rechecked the cell signal test and found that CV had increased to 15-30%, with the largest increase in the Ca v 3.3 cells. In view of the disturbance of addition caused by FLIPR, we used manual compound addition 20 min prior to the FLIPR measurement.
Fluorescent dye indicators. The FLIPR Calcium 3 Assay Kit is a fluorescence calcium indicator reagent that provides a no-wash assay format. We initially compared this no-wash dye method with the conventional incubate and wash assay using Fluo-4-AM. There was no difference in the signal-to-noise ratio (ϳ2.5) between these two dyes.
Trace metals such as zinc block Ca v 3.2 with at low micromolar concentrations. 23 Therefore we tested the effect of adding the chelator diethylenetriamine pentaacetic acid in the Fluo-4-AM loading step. We chose a diethylenetriamine pentaacetic acid concentration (1.2 mM) that would also reduce free Ca 2ϩ (buffer made with 1.3 mM CaCl 2 ), but still maintain sufficient Ca 2ϩ to keep cells adherent (ϳ0.1 mM).
Determination of optimized [Ca 2ϩ ] o to induce the response
To establish the concentration-response of [Ca 2ϩ ] o , we used four to eight wells per concentration. The replicates within the experiment yielded similar results, showing that a large signal can be induced by 10-20 mM [Ca 2ϩ ] o in the recombinant cells (Fig. 3A and B) , but not in untransfected cells (data not shown). This Ca-induced signal was approximately half the size observed after addition of the Ca ionophore ionomycin (Fig. 3, column 6 ). Since high divalent cation concentrations can reduce the apparent potency of mibefradil, 24 we routinely used 10 mM [Ca 2ϩ ] o in all subsequent experiments unless specified otherwise.
Incubation durations and temperature. Most Ca-dye assays require probenecid, an anion exchange protein inhibitor, to block extrusion of the dye from the cell. Since both the fluorescent dyes and probenecid are toxic to cells, we conducted an experiment on the loading duration (20-60 min) and temperature (room temperature vs. 37°C). In both the FlexStation and FLIPR assay, there was no effect of changing the loading time in this range, and similar results were observed at either temperature (data not shown).
Binding rates of calcium channel blockers to L-type channels are time dependent, requiring at least 10 min to reach equilibrium. 25 To test time dependence, Ca v 3.2 cells were incubated with mibefradil for varying times at 37°C, and then the response to 10 mM Ca 2ϩ was measured in the FlexStation assay. Simultaneous addition of Ca ϩ mibefradil did produce block, but mibefradil potency was enhanced by preincubation, approaching a maximum at incubation times Ͼ15 min (Fig. 3C and D) . Subsequent studies were performed after 30 min of incubation.
Drug block in the FLIPR assay. Each concentration was tested in four wells
, and most compounds were tested twice. The IC 50 values for those compounds that produced greater than 50% inhibition were automatically calculated using SRI software. Mibefradil produced a concentration-dependent inhibition of the Ca-dye signal in all three cell lines. A typical experiment testing mibefradil (columns 1-6) and lamotrigine (columns 7-12) is shown in Fig. 4A . Superimposed traces taken in the presence of varying concentrations are shown in Fig.  4B . Mibefradil displayed an IC 50 of 1.8 M when using Ca v 3.1-expressing cells (Fig. 4C, n ϭ 4) . In contrast, the Na ϩ channel blocker lamotrigine produced only weak block (IC 50 ϭ 550 M), suggesting that its antiseizure effects in childhood absence epilepsy is unlikely to be through the direct modulation of the T-type current. Typ- ical dose-responses to six compounds are shown in Fig.  4D . The Ca-induced signal often oscillated in Ca v 3.3 cells compared to the other two subtypes (Fig. 5) . In the FLEX assay, low (0.1 M) concentrations of mibefradil slowed the response to Ca with little or no effect on the maximum fluorescence observed, while higher concentrations blocked the signal almost completely. These oscillations were more apparent in the FLIPR assay because of the higher sampling frequency (Fig. 5B) .
Comparison of drug block among the FLIPR assay, IonWorks HTS assay, and conventional patch clamp
recording. To evaluate the fluorometric assay for HTS, we further conducted a comparative pharmacologic study on a set of known ion channel blockers. A variety of structurally diverse compounds, including phenylalkylamines (e.g., mibefradil), dihydropyridines (e.g., nifedipine), and piperidine antipsychotics (e.g., pimozide) were tested by both the FLIPR assay and patch clamp recordings. For compounds with known potency, their IC 50 values were used as a guideline, 26 while compounds with unknown potency were typically tested at 1, 3, 10, 30, and 100 M (maximal DMSO of 0.1%). The same sets of compounds were tested using an IonWorks HT patch system. Initial patch recordings under current clamp mode revealed resting potentials of Ca v 3 cells that varied between Ϫ15 to Ϫ40 mV. Compounds were tested in voltage clamp mode using a protocol consisting of a depolarizing test pulse to Ϫ30 mV for 500 ms, then a return to a holding potential (V h ) of Ϫ100 mV for 5 s, followed by a voltage ramp from Ϫ100 to ϩ20 mV over 800 ms. Although the whole-cell seal resistances were between 150 and 300 M⍀, the signal-to-noise ratio is excellent. T-current amplitudes ranged from 50 to 500 pA under our experimental conditions (Figs. 1B and 6A ). Optimization of cell culture, cell preparation conditions, and recording solutions improved seal resistance, stability, and overall success, increasing the patching rate from 30% to 60%. Baseline current traces (precompound) were almost superimposable with those recorded 10 s after 0.5% DMSO was applied as a control, indicating the stability of the currents recorded. Applications of several compounds (3.5 l per well) produced inhibition of the T-current in a concentration-dependent manner (Fig. 6B) . Each 384-well planar patch assay took about 1 h under this specific protocol, and one technician could conduct recordings on six to eight plates per day. A subset of compounds were also tested in conventional patch clamp recording using similar assay conditions (representative traces shown in Fig. 6C, inset) . Linear regression analysis of the IC 50 values obtained in the two assays yielded a line with a slope of 0.6 Ϯ 0.2 and a correlation coefficient of 0.8 (Fig. 6C) . Therefore the IonWorks produces reliable estimates of drug potency, although these estimates were approximately twofold lower than observed with the "gold standard" conventional patch clamp recording. Linear regression analysis of the IC 50 values obtained with FLIPR to manual patch clamp showed a steeper slope (0.7), but more scatter (Fig. 6D) . Comparison of the IonWorks results to those obtained with FLIPR again showed a slope that differed significantly from 1 (0.54), and a high correlation (Fig. 6E) . A similar discrepancy was reported previously, and a likely mechanism was proposed: drugs have higher affinities for inactivated states that predominate in the FLIPR assay compared to the rested states achieved in cells voltage clamped to Ϫ90 mV. 18 Accordingly, comparison of results obtained with eight compounds using the FlexStation and FLIPR assays showed a higher slope (0.7; data not shown).
Discussion
The main goal of this study was to establish the mechanism by which recombinant T-channels are capable of regulating intracellular calcium, and validate the use of this property for HTS. Our initial hypothesis was that Tchannels were capable of opening at the resting membrane potential of HEK293 cells. This property has been extensively studied in thalamic neurons, and contributes to their bistability: the ability to be have two distinct "resting" membrane potentials. 16 Recombinant T-channels also show the ability to generate persistent window currents, which has been estimated at ϳ2% of the total whole cell T-current. 27, 28 It was suggested that this window current was sufficient to increase intracellular Ca 2ϩ in HEK293 cells as detected by Ca-sensitive fluorescent dyes, 17 and that this signal could be used for a FLIPR assay. 18 We show that co-expression of Ca v 3. channel that is capable of hyperpolarizing the plasma membrane potential 29 eliminates this signal. The resting membrane potential of these cells is approximately Ϫ80 mV, and can be depolarized by increasing external K ϩ . 19 Consistent with this property, we show that the Ca-dye signal can be restored in this cell line by co-addition of Ca 2ϩ plus K ϩ . These results establish that the window current underlies the Ca-dye response observed when the Ca is elevated above 2 mM. We show that this response can be reliably measured in stably transfected cell lines that express one of the three recombinant Ca v 3 channels at high levels using either a FlexStation or FLIPR. Another goal of this study was to optimize the FLIPR assay for primary HTS. We also show that these cell lines are useful for secondary screening using IonWorks, an automated planar patch clamp system. Finally we validate the FLIPR assay by comparing the potency of known Ca 2ϩ channel blockers to that obtained using patch clamp electrophysiology. Similar estimates of potency have been obtained for haloperidol, mibefradil, nifedipine, pimozide, and penfluridol using manual patch clamp electrophysiology on native T-currents. 26 Therefore these methods and cell lines should be useful for HTS of compound libraries.
A selective T-channel antagonist may be useful in a variety of diseases. Recent genetic analysis of the gene encoding Ca v 3.2, CACNA1H, uncovered the presence of mutations that were only found in patients with childhood absence epilepsy. 30 Subsequent studies have shown that these mutations alter channel behavior and their trafficking to the cell surface. 28, 31 Antiepileptic drugs such as ethosuximide are useful for the treatment of absence epilepsy. Ethosuximide (at concentrations Ͼ0.1 mM) is capable of blocking native and recombinant T-channels, providing further support for the notion that a novel, more potent, and selective T-channel blocker would be a useful antiepileptic. 21, 32 Such a drug may also be useful in temporal lobe epilepsy based on the observation that Tcurrents are up-regulated in the pilocarpine model: more than 50% of rat CA1 pyramidal cells, which normally fire in regular single action potentials, are persistently converted to a bursting mode in pilocarpine-treated animals. 33 This change resulted from up-regulation of Ttype currents and underlies a long-lasting modification of neuronal firing. Other antiepileptic drugs that have been shown to block T-currents are lamotrigine and zonisamide; however, like ethosuximide, they are weak and nonspecific. [34] [35] [36] T-channel blockers may also be useful antihypertensives. The ability of mibefradil to normalize high blood pressure and to block T-type channels generated much interest in the physiology and pharmacology of the Ttype channels in the cardiovascular system. 37 However, mibefradil had to be withdrawn from the market because of drug-drug interactions. The ability of certain dihydropyridines such as efonidipine to block both T-and Ltype channels may confer additional clinical benefit over selective L-type blockers in terms of reducing both glomerular nephritis and plasma aldosterone levels. 38, 39 Recent studies have suggested some new indications for T-channel blockers, including analgesia and neuroprotection. 4, 40, 41 Inhibition of T-type currents may be useful in the treatment of neuropathic pain, based on experimental evidence obtained using mibefradil 42 or ethosuximide in animals. 43, 44 The novel neuroprotective compounds 619C89 and SB-209712 potently block T-currents at submicromolar concentrations, and this inhibition is thought to contribute to the neuroprotective effects of these compounds. However, these drugs also potently block voltage-gated Na ϩ channels, high-voltageactivated Ca 2ϩ channels, and the delayed rectifying outward K ϩ current. This poor selectivity in ion channel modulation may be associated with their side effects. 45, 46 In conclusion, a selective T-channel blocker may be useful in a variety of diseases, and HTS of recombinant channels may provide a useful assay for drug discovery.
